Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

The FDA has approved Merck’s Enflonasia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The approval is based on data ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The Conference Forum announced today the first set of keynotes for the 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference, taking place September 16-17, 2025, at the ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

The Dow Jones Industrial Average (DJINDICES: ^DJI) is loaded with blue chip stocks. It stands to reason that many Dow stocks ...